649 related articles for article (PubMed ID: 12095384)
1. Hepatitis C and progression of HIV disease.
Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
[TBL] [Abstract][Full Text] [Related]
2. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
5. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.
De Luca A; Bugarini R; Lepri AC; Puoti M; Girardi E; Antinori A; Poggio A; Pagano G; Tositti G; Cadeo G; Macor A; Toti M; D'Arminio Monforte A;
Arch Intern Med; 2002 Oct; 162(18):2125-32. PubMed ID: 12374521
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
7. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
8. The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients.
Carmo RA; Guimarães MD; Moura AS; Neiva AM; Versiani JB; Lima LV; Freitas LP; Rocha MO
Braz J Infect Dis; 2008 Jun; 12(3):173-9. PubMed ID: 18833399
[TBL] [Abstract][Full Text] [Related]
9. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.
Chung RT; Evans SR; Yang Y; Theodore D; Valdez H; Clark R; Shikuma C; Nevin T; Sherman KE;
AIDS; 2002 Sep; 16(14):1915-23. PubMed ID: 12351951
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.
Seminari E; Tinelli C; Ravasi G; Ripamonti D; Ladisa N; Marino N; Sighinolfi L; Mondello P; Migliorino M; Carosi G; Maserati R;
Curr HIV Res; 2010 Apr; 8(3):186-93. PubMed ID: 20163342
[TBL] [Abstract][Full Text] [Related]
11. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
13. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
14. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
15. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
16. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.
Lincoln D; Petoumenos K; Dore GJ;
HIV Med; 2003 Jul; 4(3):241-9. PubMed ID: 12859323
[TBL] [Abstract][Full Text] [Related]
17. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
18. Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
Dold L; Ahlenstiel G; Althausen E; Luda C; Schwarze-Zander C; Boesecke C; Wasmuth JC; Rockstroh JK; Spengler U
PLoS One; 2015; 10(8):e0134158. PubMed ID: 26241854
[TBL] [Abstract][Full Text] [Related]
19. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
Taye S; Lakew M
BMC Immunol; 2013 May; 14():23. PubMed ID: 23679118
[TBL] [Abstract][Full Text] [Related]
20. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Int J STD AIDS; 2005 Jan; 16(1):42-8. PubMed ID: 15705272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
